Follow Forum_Psych on Twitter

Display results as :

Rechercher Advanced Search

We have 222 registered users
The newest registered user is raheelmemon

Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.

Gingko Biloba for treatment of Tardive Dyskinesia in Schizophrenia

Go down

Gingko Biloba for treatment of Tardive Dyskinesia in Schizophrenia

Post  Admin on Thu Nov 15, 2012 9:34 pm

Has anyone used Gingko Biloba for treatment of Tardive Dyskinesia.
Please share your experience.
Check this interesting article below:

Extract of Ginkgo Biloba treatment for Tardive Dyskinesia in Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Trial.
Source: J Clin Psychiatry. 2011 May;72(5):615-21.

Free radicals may be involved in the pathogenesis of tardive dyskinesia (TD). Extract of Ginkgo biloba (EGb) is a potent antioxidant possessing free radical-scavenging activities. The aim of the study was to evaluate the efficacy of EGb-761, a standardized extract given in capsule form, in treating TD in schizophrenia patients.

Inpatients with DSM-IV-diagnosed schizophrenia and TD (n = 157) in a mainland China Veterans Affairs psychiatric hospital were randomly assigned to 12 weeks of treatment with either EGb-761, 240 mg/d (n = 78) or a placebo (n = 79) in a double-blind manner.
Primary outcome measures were
(1) change from baseline in the Abnormal Involuntary Movement Scale (AIMS) score and
(2) Proportion of patients with a ≥ 30% reduction in their AIMS total score at week 12.
Secondary outcome measures included
(1) Positive and Negative Syndrome Scale (PANSS) and
(2) Cognitive performance as measured by the Continuous Performance Test-37 Version and the 3-card Stroop task.
Patients were recruited for the study between December 2006 and May 2007.

- Of the 157 patients who were randomly assigned, 152 (96.8%) completed the study.
- EGb-761 treatment significantly decreased the AIMS total score in patients with TD compared to those who were given a placebo (2.13 ± 1.75 vs -0.10 ± 1.69; P < .0001), with 40 (51.3%) and 4 (5.1%) patients achieving response in the EGb-761 and placebo treatment groups, respectively.
- There were no between-group differences in the PANSS total score or cognitive measures from baseline to week 12.

EGb-761 appears to be an effective treatment for reducing the symptoms of TD in schizophrenia patients, and improvement may be mediated through the well-known antioxidant activity of this extract.

Click on to post your comments

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

Back to top Go down

Back to top

- Similar topics

Permissions in this forum:
You cannot reply to topics in this forum